Patent application number | Description | Published |
20090312559 | CATALYTIC ENANTIOSELECTIVE SILYLATIONS OF SUBSTRATES - The present invention provides methods, compositions and systems for silylation of substrates, including direct asymmetric silylation of a substrate to provide enantiomerically enriched silylated products. | 12-17-2009 |
20110015430 | CATALYSTS AND PROCESSES FOR THE FORMATION OF TERMINAL OLEFINS BY ETHENOLYSIS - The present invention relates generally to catalysts and processes for the formation of terminal olefin(s) from internal olefin(s) via ethenolysis reactions. The ethenolysis reactions may proceed with high conversion, high turnover, and/or high selectivity. | 01-20-2011 |
20110065915 | CATALYSTS FOR METATHESIS REACTIONS INCLUDING ENANTIOSELECTIVE OLEFIN METATHESIS, AND RELATED METHODS - The present invention provides compositions comprising metal complexes, and related methods. In some embodiments, metal complexes of the invention may be useful as catalysts for chemical reactions, including metathesis reactions, wherein the catalysts exhibit enhanced activity and stereoselectivity. In some embodiments, the invention may advantageously provide metal complexes comprising a stereogenic metal atom. Such metal complexes may be useful in enantioselective catalysis. | 03-17-2011 |
20110245477 | EFFICIENT METHODS FOR Z- OR CIS-SELECTIVE CROSS-METATHESIS - The present invention generally relates to methods for performing metathesis reactions, including cross-metathesis reactions. Methods described herein exhibit enhanced activity and stereoselectivity, relative to known methods, and are useful in the synthesis of a large assortment of biologically and therapeutically significant agents. | 10-06-2011 |
20120302710 | COMPLEXES FOR USE IN METATHESIS REACTIONS - The present invention relates generally to metal complexes, methods for preparation and uses of the same. | 11-29-2012 |
20120323000 | Z-SELECTIVE RING-CLOSING METATHESIS REACTIONS - The present invention relates generally to olefin metathesis. In some embodiments, the present invention provides methods for Z-selective ring-closing metathesis. | 12-20-2012 |
20130116434 | TUNGSTEN OXO ALKYLIDENE COMPLEXES FOR Z SELECTIVE OLEFIN METATHESIS - The current application describes tungsten oxo alkylidene complexes for olefin metathesis. | 05-09-2013 |
20130274482 | HIGHLY Z-SELECTIVE OLEFINS METATHESIS - The present invention relates generally to catalysts and processes for the Z-selective formation of internal olefin(s) from terminal olefin(s) via homo-metathesis reactions. | 10-17-2013 |
20140371454 | CATALYSTS FOR EFFICIENT Z-SELECTIVE METATHESIS - The present application provides, among other things, compounds and methods for metathesis reactions. In some embodiments, provided compounds promote highly efficient and highly Z-selective metathesis. In some embodiments, provided compounds and methods are particularly useful for producing allyl alcohols. In some embodiments, provided compounds have the structure of formula I. In some embodiments, provided compounds comprise ruthenium, and a ligand bonded to ruthenium through a sulfur atom. | 12-18-2014 |
20150057451 | SIMPLE ORGANIC MOLECULES AS CATALYSTS FOR PRACTICAL AND EFFICIENT ENANTIOSELECTIVE SYNTHESIS OF AMINES AND ALCOHOLS - The present invention provides organic molecules and methods thereof for reactions between organoboron reagents and double bonds, such as imines or carbonyls, to stereoselectively provide chiral products including amines and alcohols, entities useful for the preparation of biologically active molecules. | 02-26-2015 |
Patent application number | Description | Published |
20090170757 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR - The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders. | 07-02-2009 |
20110288163 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR - The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders. | 11-24-2011 |
20120071412 | METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS - The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed gastrointestinal motility including, but not limited to, post-surgical gastroparesis and post-operative ileus in combination with opioid-induced bowel dysfunction. These agents are effective for multiple disorders at dose levels equivalent to those required to treat a single disorder. | 03-22-2012 |